Drug Interaction Study - effect of AZD5672 on the pharmacokinetics of Digoxin
Study identifier:D1710C00021
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label Study to Assess the Effect of AZD5672 at Steady State on the Pharmacokinetics of Digoxin Following Single Dose Administration in Healthy Volunteers
Medical condition
Healthy Volunteers, pharmacokinetics
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5672, Digoxin
Sex
All
Actual Enrollment
24
Study type
Interventional
Age
18 Years - 50 Years
Date
Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD5672 + Digoxin (single dose on day 12) | Drug: AZD5672 50 mg, for 13 days Drug: Digoxin 0.5mg dose Other Name: Lanoxin |
| Experimental: 2 AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12) | Drug: AZD5672 50 mg, for 13 days Drug: Digoxin 0.5mg dose Other Name: Lanoxin |
Contacts
Investigators
Principal Investigator
Rod Hepburn
AstraZeneca R&D, Charnwood, UK
